SEC Form 4 · accession 0001003642-16-000051
Impax Laboratories, LLC · IPXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J Kevin Buchi
Director
Period of report
Nov 23, 2016
Accepted (ET)
Nov 28, 2016 · 4:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001003642
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 23, 2016 | A | 8,020 | $0.00 | A | 8,020 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right-to-Buy)F1 | $14.45 | Nov 23, 2016 | A | 20,445 | A | — | Nov 23, 2026 | Common Stock | 20,445 | 20,445 | D |
Explanation of responses
- F1The option fully vests on the earlier of (i) November 23, 2017, which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders.
Remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.